CMBA
PCRX icon

C.M. Bidwell & Associates’s Pacira BioSciences PCRX Stock Holding History

C.M. Bidwell & Associates’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,700
Closed -$283K – 524
2020
Q3 		$283K Buy
+4,700
New +$273K 0.26% 71
2020
Q2 		– Sell
-875
Closed -$29K – 447
2020
Q1 		$29K Buy
+875
New +$36.3K 0.03% 226
2019
Q3 		– Sell
-1,020
Closed -$44K – 469
2019
Q2 		$44K Buy
+1,020
New +$43.3K 0.04% 254

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

C.M. Bidwell & Associates's PCRX Position: Q4 2020 in Review

C.M. Bidwell & Associates sold out of Pacira BioSciences (PCRX) in Q4 2020, closing a stake of 4,700 shares — an estimated $283K sold.

C.M. Bidwell & Associates first reported a position in PCRX in Q2 2019 and held it in 3 quarters. The position peaked at $283K in Q3 2020. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2020.

  • C.M. Bidwell & Associates reported no remaining Pacira BioSciences position as of Q4 2020 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 4,700 Pacira BioSciences shares in Q4 2020, an estimated $283K.
  • C.M. Bidwell & Associates first reported a position in Pacira BioSciences in Q2 2019 and held it in 3 quarters.
  • C.M. Bidwell & Associates's Pacira BioSciences position peaked at $283K in Q3 2020.
  • 260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2020.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2020, filed 16 Feb 2021.